11.01.2013 • News • Brenntag • Altivia • Mergers & Acquisitions (M&A)

Brenntag Acquires US Distributor of Water Treatment Chemicals

Brenntag, the global chemical distributor, has acquired Altivia Corporation, a water treatment chemical distributor headquartered in Houston, Texas. Altivia has facilities in Houston, Texas, St. Gabriel, Louisiana and Marlow, Oklahoma.

Altivia Chemicals's aluminum polymers manufacturing business and the ferric and ferrous sulfate production facilities in Pasadena, Texas are not part of this transaction which was closed on December 31, 2012.

Altivia formulates, blends, repackages and distributes water treatment chemicals. In addition, Altivia serves a wide variety of customer industries with products such as bleach, aluminum sulfate, specialty polymers, caustic soda, chlorine and sulfuric acid. For the financial year 2012 the company is expected to generate sales of $83 million.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Top-Feature

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.